U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C22H34NO2.I
Molecular Weight 471.4153
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXAPIUM IODIDE

SMILES

[I-].C[N+]4(CC1COC(O1)(C2CCCCC2)C3=CC=CC=C3)CCCCC4

InChI

InChIKey=YHEWVHONOOWLMW-UHFFFAOYSA-M
InChI=1S/C22H34NO2.HI/c1-23(15-9-4-10-16-23)17-21-18-24-22(25-21,19-11-5-2-6-12-19)20-13-7-3-8-14-20;/h2,5-6,11-12,20-21H,3-4,7-10,13-18H2,1H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula HI
Molecular Weight 127.9124
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H34NO2
Molecular Weight 344.5109
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01815 and http://america.pink/oxapium-iodide_3370799.html

Oxapium iodide (ciclonium or cyclonium, trade name Oxaperan, Esperan) is an antispasmodic indicated for the treatment of gastritis, gastroduodenal ulcer, enteritis, and other conditions. It is marketed in South Korea by Dongsung Pharmaceuticals and by Taisho Toyama Pharmaceutical Co., Ltd. in Japan. Oxapium is a muscarinic cholinergic receptor antagonist. It has two separate pharmacological effects: (1) a potent atropine-like action, (2) a papaverine-like action.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ESPERAN

Approved Use

Improvement of pain due to spasms and motility disorder in the following diseases: Gastritis, Gastroduodenal ulcer, Enteritis, Gallbladder and biliary disease, Urinary calculus

Launch Date

1971
Palliative
ESPERAN

Approved Use

Improvement of pain due to spasms and motility disorder in the following diseases: Gastritis, Gastroduodenal ulcer, Enteritis, Gallbladder and biliary disease, Urinary calculus

Launch Date

1971
Palliative
ESPERAN

Approved Use

Improvement of pain due to spasms and motility disorder in the following diseases: Gastritis, Gastroduodenal ulcer, Enteritis, Gallbladder and biliary disease, Urinary calculus

Launch Date

1971
PubMed

PubMed

TitleDatePubMed
[The effects of 1,3-dioxolane derivative (Esperan) on the smooth muscle and its intrinsic nerves of guinea-pig stomach (author's transl)].
1974 Mar
Patents

Sample Use Guides

For oral use, the usual adult dosage is 30-60 mg as oxapium iodide daily in 3 divided doses.
Route of Administration: Oral
The excitatory nerve response by electrical stimulation was rapidly and completely suppressed by Oxapium (esperan) (0.1 ug/m/)
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:55:56 GMT 2023
Edited
by admin
on Fri Dec 15 16:55:56 GMT 2023
Record UNII
682380CG4N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXAPIUM IODIDE
INN   MART.   WHO-DD  
INN  
Official Name English
OXAPIUM IODIDE [JAN]
Common Name English
1-((2-CYCLOHEXYL-2-PHENYL-1,3-DIOXOLAN-4-YL)METHYL)-1-METHYLPIPERIDINIUM IODIDE
Systematic Name English
ESPALEXAN
Brand Name English
SH 100
Code English
OXAPIUM IODIDE [MART.]
Common Name English
oxapium iodide [INN]
Common Name English
SH-100
Code English
CYCLONIUM IODIDE [MI]
Common Name English
Oxapium iodide [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
Code System Code Type Description
PUBCHEM
168884
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
ChEMBL
CHEMBL1725250
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
MESH
C029013
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
EVMPD
SUB09499MIG
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
SMS_ID
100000083011
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID6046925
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
FDA UNII
682380CG4N
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
CAS
6577-41-9
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
MERCK INDEX
m3999
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
OXAPIUM IODIDE
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
NCI_THESAURUS
C90697
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
INN
3126
Created by admin on Fri Dec 15 16:55:56 GMT 2023 , Edited by admin on Fri Dec 15 16:55:56 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY